Xintian Pharmaceutical: The company’s product gross profit margin is relatively high, and the impact of price increases of Chinese medicinal materials is relatively controllable_Oriental Fortune Net

Summary

[Xintian Pharmaceutical: The company’s product gross profit margin is relatively high and the impact of price increases of Chinese herbal medicines is relatively controllable]Xintian Pharmaceutical said during institutional research that in 2021, the company will achieve certain results in cost control, with a gross profit margin of 79.26%. On the one hand, initial results have been achieved by reducing costs and increasing efficiency, on the other hand, the company has a certain supply reserve of raw materials. At present, the company has not built its own medicinal material planting base. Regarding the construction of medicinal material planting base, relevant planning and arrangements will be made according to the actual situation. The company’s product gross profit margin is relatively high. Under the condition that the price of traditional Chinese medicinal materials continues to rise and the existing sales price remains unchanged, it is expected to have a certain impact on the company’s gross profit margin, but the impact is relatively controllable.

　　Xintian PharmaceuticalexistInstitutional researchShi said that in 2021, the company will achieve certain results in cost control.interest rateIt was 79.26%. On the one hand, initial results were achieved in reducing costs and increasing efficiency, and on the other hand, the company had a certain supply of raw materials. At present, the company has not built its own medicinal material planting base. Regarding the construction of medicinal material planting base, relevant planning and arrangements will be made according to the actual situation.Company product grossinterest raterelatively high, intraditional Chinese medicineUnder the condition that the price of materials continues to rise and the existing sales price remains unchanged, it is expected to have a certain impact on the company’s gross profit margin, but the impact is relatively controllable.

(Article Source:securitiesTimes e company)

Article source: Securities Times · e company

Responsible editor: 65

Original title: Xintian Pharmaceutical: The company’s product gross profit margin is relatively high, and the impact of price increases of Chinese medicinal materials is relatively controllable